Oct 2, 2026 06:04AM
Oct 2, 2026 02:30AM
Sep 29, 2026 12:12PM
Sep 28, 2026 05:33PM
Sep 28, 2026 05:30PM
Sep 25, 2026 07:01AM
Sep 25, 2026 07:00AM Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
Sep 25, 2026 06:02AM
Sep 18, 2026 06:09AM
Sep 14, 2026 04:29AM
Sep 14, 2026 04:29AM
Sep 13, 2026 09:55PM
Sep 13, 2026 09:47PM
Sep 13, 2026 09:45PM Enhertu shows 14.3-month PFS in first-line lung cancer trial
Sep 13, 2026 09:45PM
Sep 8, 2026 09:01AM
Sep 8, 2026 09:00AM
Sep 8, 2026 07:50AM
Sep 8, 2026 07:50AM
Sep 7, 2026 05:55PM
Sep 4, 2026 07:03PM ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Sep 4, 2026 03:41PM
Sep 1, 2026 07:00AM
Sep 1, 2026 07:00AM
Sep 1, 2026 06:09AM
Aug 27, 2026 07:00AM
Aug 26, 2026 09:20AM
Aug 26, 2026 07:00AM Daiichi Sankyo and AstraZeneca start phase 3 urothelial cancer trial
Aug 26, 2026 07:00AM
Aug 17, 2026 07:30AM
Aug 17, 2026 07:00AM
Aug 17, 2026 02:30AM
Aug 17, 2026 02:30AM
Jul 27, 2026 06:06AM
Jun 22, 2026 08:30AM Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Jun 15, 2026 03:00AM
Jun 12, 2026 06:44PM
Jun 12, 2026 02:03PM
Jun 2, 2026 08:02AM
Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM
May 28, 2026 09:18PM IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 28, 2026 12:42PM
May 27, 2026 04:04AM
May 22, 2026 10:17AM
May 22, 2026 10:16AM
May 22, 2026 09:30AM
May 22, 2026 09:30AM
May 22, 2026 08:00AM Enhertu gets EU panel backing for HER2 positive metastatic solid tumors
May 22, 2026 08:00AM

332,802 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All